| Description |
1 online resource (1039 pages) : illustrations (some color), portraits |
| Series |
Pan Stanford series on nanomedicine ; vol. 3 |
|
Pan Stanford series on nanomedicine ; v. 3.
|
| Contents |
Cover; Half Title; Title Page; Copyright Page; Dedication; About the Editors; Table of Contents; List of Corresponding Authors; Foreword; My Life with Biologicals and Nanodrugs: A Twenty-Year Affair; 1: Current Immune Aspects of Biologics and Nanodrugs: An Overview; 1.1 Introduction; 1.2 Biologics versus Small-Molecule Drugs; 1.3 What Are Nanodrugs?; 1.4 Are Biologics and Nanodrugs Adversely Immunogenic?; 1.5 Immunogenicity Assessment of Biologics and Nanodrugs; 1.6 Entering the Era of Biosimilars; 1.7 Immune Aspects of Biosimilars and Nanosimilars: The Copaxone® Example |
|
1.8 Concluding Remarks and Future Directions2: Immunological Issues with Medicines of Nano Size: The Price of Dimension Paradox; 2.1 Adverse Immune Effects of Nanodrugs; 2.2 Issues of Terminology; 2.3 Adverse Immune Effects of Nanodrugs: The Dimension Paradox; 2.4 Vicious Cycle between Specific and Nonspecific Immune Responses to Nanodrugs; 2.5 CARPA as Blood Stress; 2.6 CARPA Testing; 3: Immunotherapy and Vaccines; 3.1 Introduction; 3.2 The Immune System; 3.3 Nanotechnology in Vaccines; 3.4 Conclusions; 4: Site-Specific Antibody Conjugation for ADC and Beyond; 4.1 Introduction |
|
4.2 Site-Specific ADC through Specific Amino Acids4.3 Site-Specific ADC through Unnatural Amino Acids; 4.4 Site-Specific ADC through Glycans; 4.5 Site-Specific ADC through Short Peptide Tags; 4.6 Site-Specific Antibody Conjugation for Diagnosis; 4.7 Site-Specific Antibody Conjugation for Other Therapeutic Applications; 4.8 Conclusions; 5: Current Understanding of Interactions between Nanoparticles and the Immune System; 5.1 Introduction; 5.2 Achievements; 5.3 Disappointments; 5.4 Lessons Learned; 5.5 Conclusions; 6: Auto-antibodies as Biomarkers for Disease Diagnosis; 6.1 Introduction |
|
6.2 Auto-antibodies as Biomarkers6.3 Auto-antibodies for Companion Diagnostics Enabling Personalized Medicine; 6.4 Biomarker Discovery Strategies; 6.5 Antigen/ Auto-antibody Interactions as Biomarker Candidates; 6.6 Diagnostic Assays Based on Antigen/ Auto-antibody Interactions; 6.7 Conclusion; 7: The Acceleated Blood Clearance Phenomenon of PEGylated Nanocarriers; 7.1 Introduction; 7.2 Mechanism of ABC Phenomenon; 7.3 Correlation Between Complement Activation and ABC Phenomenon; 7.4 Factors That Affect the Magnitude of the ABC Phenomenon |
|
7.5 Strategies to Abrogate/ Attenuate Induction of the ABC Phenomenon7.6 Clinical Implications of ABC Phenomenon; 7.7 Conclusion; 8: Anti-PEG Immunity Against PEGylated Therapeutics; 8.1 Introduction; 8.2 PEG Immunogenicity in Animal Models; 8.3 PEG Immunogenicity in Humans; 8.4 Properties of Anti-PEG Antibody Epitope; 8.5 Strategies to Avert Anti-PEG Antibody Responses; 8.6 Conclusion; 9: Complement Activation: Challenges to Nanomedicine Development; 9.1 Introduction; 9.2 C Activation Pathways and Downstream Effectors; 9.3 Role of C in Human Health and Disease |
| Summary |
"The enormous advances in the immunologic aspects of biotherapeutics and nanomedicines in the past two decades has necessitated an authoritative and comprehensive reference source that can be relied upon by immunologists, biomedical researchers, clinicians, pharmaceutical companies, regulators, venture capitalists, and policy makers alike. This text provides a thorough understanding of immunology, therapeutic potential, clinical applications, adverse reactions, and approaches to overcoming immunotoxicity of biotherapeutics and nanomedicines. It also tackles critical, yet often overlooked topics such as immune aspects of nano-bio interactions, current FDA regulatory guidances, complement activation-related pseudoallergy (CARPA), advances in nanovaccines, and immunogenicity testing of protein therapeutics"--Publisher's description |
| Notes |
9.4 Complement Activation by Biomaterials |
|
Print version record |
| Subject |
Immunotherapy.
|
|
Biological products -- Therapeutic use.
|
|
Nanomedicine.
|
|
Biological Products -- immunology
|
|
Nanostructures -- therapeutic use
|
|
Nanostructures -- adverse effects
|
|
Nanomedicine -- methods
|
|
Biopharmaceutics -- methods
|
|
Immunotherapy
|
|
Biological Therapy
|
|
Nanomedicine
|
| Form |
Electronic book
|
| Author |
Bawa, Raj, editor.
|
|
Szebeni, János, 1954- editor.
|
|
Webster, Thomas J., 1971- editor.
|
|
Audette, Gerald F., editor.
|
| ISBN |
9781351399784 |
|
1351399780 |
|
9780203731536 |
|
0203731530 |
|
